Sarepta Therapeutics: Buy Rating Affirmed on Positive EMBARK Study Results and Strong Financial Outlook
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The ...